Fiera Capital Corp trimmed its stake in shares of Repligen Co. (NASDAQ:RGEN) by 3.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 32,116 shares of the biotechnology company’s stock after selling 1,154 shares during the period. Fiera Capital Corp owned 0.06% of Repligen worth $3,101,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of RGEN. Penserra Capital Management LLC purchased a new position in Repligen during the fourth quarter valued at $28,000. NumerixS Investment Technologies Inc purchased a new position in Repligen during the fourth quarter valued at $29,000. Nisa Investment Advisors LLC grew its stake in Repligen by 62.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 470 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 180 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in Repligen during the fourth quarter valued at $66,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new position in shares of Repligen in the 4th quarter worth $119,000. 83.53% of the stock is owned by institutional investors.
In related news, Director Karen A. Dawes sold 517 shares of Repligen stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $139.44, for a total transaction of $72,090.48. Following the completion of the sale, the director now owns 119,946 shares in the company, valued at approximately $16,725,270.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Anthony Hunt sold 11,735 shares of Repligen stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $91.56, for a total transaction of $1,074,456.60. Following the sale, the chief executive officer now owns 231,148 shares of the company’s stock, valued at approximately $21,163,910.88. The disclosure for this sale can be found here. Insiders sold a total of 98,307 shares of company stock valued at $10,330,055 in the last 90 days. Company insiders own 1.70% of the company’s stock.
A number of brokerages have commented on RGEN. SVB Leerink lifted their price objective on shares of Repligen from $115.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. ValuEngine cut shares of Repligen from a “buy” rating to a “hold” rating in a research note on Friday, May 1st. HC Wainwright lifted their price objective on shares of Repligen from $100.00 to $143.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. BidaskClub raised shares of Repligen from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 14th. Finally, Stifel Nicolaus dropped their price objective on shares of Repligen from $116.00 to $113.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Repligen presently has a consensus rating of “Buy” and a consensus price target of $125.29.
Repligen stock opened at $139.51 on Friday. The firm has a 50-day moving average price of $114.09 and a 200-day moving average price of $98.39. The firm has a market capitalization of $7.34 billion, a PE ratio of 128.73, a price-to-earnings-growth ratio of 5.62 and a beta of 1.06. The company has a current ratio of 15.56, a quick ratio of 14.09 and a debt-to-equity ratio of 0.25. Repligen Co. has a 12-month low of $66.21 and a 12-month high of $143.93.
Repligen (NASDAQ:RGEN) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.10. The firm had revenue of $76.09 million during the quarter, compared to analyst estimates of $71.79 million. Repligen had a net margin of 8.11% and a return on equity of 5.55%. The business’s revenue was up 25.5% on a year-over-year basis. During the same quarter last year, the business earned $0.28 EPS. As a group, sell-side analysts predict that Repligen Co. will post 1.13 earnings per share for the current fiscal year.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Recommended Story: How to interpret Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.